-

Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant

Children’s Afrin® products provide ridiculously FAST nasal congestion relief, so busy parents can get their families back on track. The WOW is REAL!

WHIPPANY, N.J.--(BUSINESS WIRE)--Afrin®, the #1 doctor and pharmacist recommended nasal spray brand1, announced today the launch of Children’s Afrin®, the children's acute medicated nasal spray that works fast and lasts up to 12 hours. Available in retail stores nationwide, the line of children’s medicated consumer products includes Afrin® Extra Moisturizing Stuffy Nose Spray and Afrin® No Drip Extra Moisturizing Stuffy Nose Spray.

Children’s Afrin® provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. The children’s medicated product line offers nasal spray products for children two to six and six and up:

  • Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old, is specially formulated for young children and unblocks a stuffy nose fast
  • Afrin® No Drip Extra Moisturizing Stuffy Nose Pump Mist, for ages six years old and up, targets nasal congestion in seconds without dripping down the nose or throat

“There’s nothing worse than when you’re almost out the door, and your child runs over with their stuffy and snotty nose complaining of being sick because you know your plans for the day have been thwarted. That’s why we’re excited to bring the power of Afrin’s fast congestion relief to the whole family, so all ages can breathe more freely,” said Catherine Vennat, VP/GM, Upper Respiratory, Bayer Consumer Health U.S. “Children suffering from colds or allergies now have access to nasal congestion relief that works fast and allows children to feel like themselves again, and their busy parents to get their families back on track while juggling multiple responsibilities.”

The nasal sprays offer fast relief to children for up to 12 hours, providing comfort to children and their parents, all day or all night. Children’s Afrin® Medicated Nasal Sprays are available at mass retail locations. For more information, please visit https://www.afrin.com/ or follow us on Instagram and Twitter.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1 Pharmacy Times Survey 2020

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

More News From Bayer

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio...

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key Facts The sNDA was supported by the Phase III FINE-ONE trial, which showed KERENDIA significantly reduced urine albumin-to-creatinine rati...

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT’S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OC...
Back to Newsroom